Evropska unija - norveščina - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatide - diabetes mellitus, type 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Evropska unija - norveščina - EMA (European Medicines Agency)

sanofi winthrop industrie - insulin glargine, lixisenatide - diabetes mellitus, type 2 - legemidler som brukes i diabetes - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sglt-2 inhibitors.

Norveška - norveščina - Statens legemiddelverk

orifarm as - vortioksetinhydrobromid - tablett, filmdrasjert - 5 mg

Norveška - norveščina - Statens legemiddelverk

orifarm as - vortioksetinhydrobromid - tablett, filmdrasjert - 10 mg

Norveška - norveščina - Statens legemiddelverk

2care4 aps - vortioksetinhydrobromid - tablett, filmdrasjert - 20 mg

Evropska unija - norveščina - EMA (European Medicines Agency)

recordati rare diseases - osilodrostat fosfat - cushing syndrome - kortikosteroider for systemisk bruk - isturisa er angitt for behandling av endogent cushings syndrom hos voksne.

Evropska unija - norveščina - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv-infeksjoner - antivirale midler til systemisk bruk - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Evropska unija - norveščina - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegravir - hiv-infeksjoner - antivirale midler til systemisk bruk - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 og 5.

Norveška - norveščina - Statens legemiddelverk

orifarm as - vortioksetinhydrobromid - tablett, filmdrasjert - 20 mg

Norveška - norveščina - Statens legemiddelverk

sandoz - københavn - kandesartancileksetil / hydroklortiazid - tablett - 16 mg / 12.5 mg